Lisata Acquires Marea Therapeutics with $225M Private Placement
LSTA sits 49% above its 52-week low of $0.988 on light trading volume (0.4× avg).
Summary
Lisata Therapeutics is acquiring Marea Therapeutics and raising $225 million in a concurrent private placement. The merger closed September 17, 2026; Lisata issued 1,793,129 common shares and 211,365.213 Series C preferred shares to Marea stockholders, and sold 150,867.995 Series C preferred shares for about $225 million in the PIPE, with closing expected September 18, 2026. This is a transformative deal for a company that recently terminated its merger with Kuva Labs and cut 72% of its workforce. The acquisition brings new assets and the financing provides runway. The $225 million raise is highly dilutive given Lisata's $13 million market cap, but it signals investor confidence in the new direction. Watch for details on Marea's pipeline and the terms of the private placement.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The merger closed September 17, 2026; Lisata issued 1,793,129 common shares and 211,365.213 Series C preferred shares to Marea stockholders, and sold 150,867.995 Series C preferred shares for about $225 million in the PIPE, closing expected September 18, 2026.
At the time of this announcement, LSTA was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $0.99 to $5.07. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.